Objective:The aim of this study was to discover the potential biomarkers changes on a rat model of isoproterenol (ISO) induced myocardial ischaemia before and after treatment with a Xiangdan submicron emulsion and to ...Objective:The aim of this study was to discover the potential biomarkers changes on a rat model of isoproterenol (ISO) induced myocardial ischaemia before and after treatment with a Xiangdan submicron emulsion and to explore the unclearing mechanisms by urinary metabolomics.Methods:Three active traditional Chinese medicine (TCM) ingredients were formulated into a lyophilized submicron emulsion powder with hydroxypropyl-β-cyclodextrin encapsulation by high pressure homogenization technology.The three ingredients were given both separately and combined,and the corresponding effects of the three drugs were compared.Principal component analysis (PCA) and the HPLC-UV analytical method was applied to explore the change of composition of urine metabolites in a rat model of isoproterenol induced myocardial ischaemia.Results:Analytical methods measuring the three active ingredients in urine samples were established.PCA score plots revealed that the therapeutic effect of the Xiangdan submicron emulsion was more significant than that of the Xiangdan injection.There was a synergistic effect among the three active ingredients.Furthermore,studies of rat metabolism changes and structure analysis of biological markers indicated that the mechanism of Xiangdan formulations was related to the inhibition of abnormal tryptophan metabolism.Conclusion:Xiangdan preparations had a confirmed effect in the treatment of coronary heart disease,especially with the novel Xiangdan submicron emulsion formulation.Urinary metabolomics methods to monitor special biomarker changes is an excellent method to reveal the mechanism of action of TCM drugs.展开更多
目的探究香丹注射液联合奥美拉唑注射液治疗急性胰腺炎(acute pancreatitis,AP)的疗效及对血清脂肪酸结合蛋白(fatty acid binding protein,FABP)4、高迁移率族蛋白B1(high mobility group protein B1,HMGB-1)水平的影响。方法根据简单...目的探究香丹注射液联合奥美拉唑注射液治疗急性胰腺炎(acute pancreatitis,AP)的疗效及对血清脂肪酸结合蛋白(fatty acid binding protein,FABP)4、高迁移率族蛋白B1(high mobility group protein B1,HMGB-1)水平的影响。方法根据简单排序随机化法将本院2023年4月至2024年04月确诊的74例AP患者分为奥美拉唑组(奥美拉唑注射液)和香丹组(奥美拉唑注射液联合香丹注射液),每组37例。比较两组临床疗效、炎症因子水平、免疫功能指标、肠黏膜屏障功能指标、血液流变学指标以及治疗期间的不良反应情况。结果奥美拉唑组治疗总有效率低于香丹组(56.76%vs 81.08%,P<0.05);治疗后,香丹组腹痛、肠鸣音、腹胀等症状缓解时间及住院时间均短于奥美拉唑组(P<0.05);两组降钙素原、C反应蛋白、白介素-6、白介素-8、二胺氧化、D-乳酸、内毒素、血液流变学指标、FABP4以及HMGB-1均比治疗前降低(P<0.05),且香丹组降低更明显(P<0.05);两组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均较治疗前升高,且香丹组升高更显著(P<0.05)。结论香丹注射液联合奥美拉唑注射液治疗AP患者疗效明显,可显著降低FABP4、HMGB-1水平,减轻患者炎症反应,提高患者免疫力和肠道屏障功能,改善血液流变学,安全性较高。展开更多
文摘Objective:The aim of this study was to discover the potential biomarkers changes on a rat model of isoproterenol (ISO) induced myocardial ischaemia before and after treatment with a Xiangdan submicron emulsion and to explore the unclearing mechanisms by urinary metabolomics.Methods:Three active traditional Chinese medicine (TCM) ingredients were formulated into a lyophilized submicron emulsion powder with hydroxypropyl-β-cyclodextrin encapsulation by high pressure homogenization technology.The three ingredients were given both separately and combined,and the corresponding effects of the three drugs were compared.Principal component analysis (PCA) and the HPLC-UV analytical method was applied to explore the change of composition of urine metabolites in a rat model of isoproterenol induced myocardial ischaemia.Results:Analytical methods measuring the three active ingredients in urine samples were established.PCA score plots revealed that the therapeutic effect of the Xiangdan submicron emulsion was more significant than that of the Xiangdan injection.There was a synergistic effect among the three active ingredients.Furthermore,studies of rat metabolism changes and structure analysis of biological markers indicated that the mechanism of Xiangdan formulations was related to the inhibition of abnormal tryptophan metabolism.Conclusion:Xiangdan preparations had a confirmed effect in the treatment of coronary heart disease,especially with the novel Xiangdan submicron emulsion formulation.Urinary metabolomics methods to monitor special biomarker changes is an excellent method to reveal the mechanism of action of TCM drugs.
文摘目的探究香丹注射液联合奥美拉唑注射液治疗急性胰腺炎(acute pancreatitis,AP)的疗效及对血清脂肪酸结合蛋白(fatty acid binding protein,FABP)4、高迁移率族蛋白B1(high mobility group protein B1,HMGB-1)水平的影响。方法根据简单排序随机化法将本院2023年4月至2024年04月确诊的74例AP患者分为奥美拉唑组(奥美拉唑注射液)和香丹组(奥美拉唑注射液联合香丹注射液),每组37例。比较两组临床疗效、炎症因子水平、免疫功能指标、肠黏膜屏障功能指标、血液流变学指标以及治疗期间的不良反应情况。结果奥美拉唑组治疗总有效率低于香丹组(56.76%vs 81.08%,P<0.05);治疗后,香丹组腹痛、肠鸣音、腹胀等症状缓解时间及住院时间均短于奥美拉唑组(P<0.05);两组降钙素原、C反应蛋白、白介素-6、白介素-8、二胺氧化、D-乳酸、内毒素、血液流变学指标、FABP4以及HMGB-1均比治疗前降低(P<0.05),且香丹组降低更明显(P<0.05);两组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均较治疗前升高,且香丹组升高更显著(P<0.05)。结论香丹注射液联合奥美拉唑注射液治疗AP患者疗效明显,可显著降低FABP4、HMGB-1水平,减轻患者炎症反应,提高患者免疫力和肠道屏障功能,改善血液流变学,安全性较高。
